CN1630863B - 人gsk3的结晶方法及其新的晶体结构 - Google Patents

人gsk3的结晶方法及其新的晶体结构 Download PDF

Info

Publication number
CN1630863B
CN1630863B CN03803641XA CN03803641A CN1630863B CN 1630863 B CN1630863 B CN 1630863B CN 03803641X A CN03803641X A CN 03803641XA CN 03803641 A CN03803641 A CN 03803641A CN 1630863 B CN1630863 B CN 1630863B
Authority
CN
China
Prior art keywords
atom
gsk3
leu
arg
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03803641XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1630863A (zh
Inventor
D·E·布西里
V·P·乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN1630863A publication Critical patent/CN1630863A/zh
Application granted granted Critical
Publication of CN1630863B publication Critical patent/CN1630863B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN03803641XA 2002-02-11 2003-02-11 人gsk3的结晶方法及其新的晶体结构 Expired - Fee Related CN1630863B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35591602P 2002-02-11 2002-02-11
US60/355,916 2002-02-11
PCT/US2003/004456 WO2003068932A2 (fr) 2002-02-11 2003-02-11 Methode de cristallisation de gsk3 humain et nouvelle structure cristalline associee

Publications (2)

Publication Number Publication Date
CN1630863A CN1630863A (zh) 2005-06-22
CN1630863B true CN1630863B (zh) 2010-06-09

Family

ID=27734586

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03803641XA Expired - Fee Related CN1630863B (zh) 2002-02-11 2003-02-11 人gsk3的结晶方法及其新的晶体结构

Country Status (6)

Country Link
US (2) US20070020745A1 (fr)
EP (1) EP1504368A4 (fr)
JP (1) JP2005532265A (fr)
CN (1) CN1630863B (fr)
AU (1) AU2003225569A1 (fr)
WO (1) WO2003068932A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105132393A (zh) * 2015-09-12 2015-12-09 复旦大学 一种深海耐盐、耐碱蛋白酯酶的表达和纯化、晶体结构及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE433751T1 (de) * 2001-04-30 2009-07-15 Vertex Pharma Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen
TWI654689B (zh) * 2008-12-26 2019-03-21 日商半導體能源研究所股份有限公司 半導體裝置及其製造方法
CN103310045B (zh) * 2013-05-28 2015-12-23 山东师范大学 一种利用增强现实技术进行晶体大分子三维可视化的方法
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044246A1 (fr) * 1999-12-17 2001-06-21 Chiron Corporation Inhibiteurs bicycliques de synthase kinase 3 de glycogene
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
WO2002010357A2 (fr) * 2000-07-27 2002-02-07 Chiron Corporation Polypeptides gsk3

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5978740A (en) * 1995-08-09 1999-11-02 Vertex Pharmaceuticals Incorporated Molecules comprising a calcineurin-like binding pocket and encoded data storage medium capable of graphically displaying them
US6057117A (en) * 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
AU2625201A (en) * 2000-01-03 2001-07-16 Ramot University Authority For Applied Research And Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
KR100793263B1 (ko) * 2000-09-19 2008-01-10 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 ＧＳＫ-3β 단백질의 특성확인 및 그것의 이용 방법
AU2002222274A1 (en) * 2000-12-18 2002-07-01 Smithkline Beecham Plc Crystal structure of glycogen synthase kinase 3 beta
ATE433751T1 (de) * 2001-04-30 2009-07-15 Vertex Pharma Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
US20080201123A1 (en) * 2006-08-17 2008-08-21 The Penn State Research Foundation Increased activity and efficiency of expansin-like proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1312807A (zh) * 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
WO2001044246A1 (fr) * 1999-12-17 2001-06-21 Chiron Corporation Inhibiteurs bicycliques de synthase kinase 3 de glycogene
WO2002010357A2 (fr) * 2000-07-27 2002-02-07 Chiron Corporation Polypeptides gsk3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aoki M, et al.Expression, purification and crystallization of humantau-protein kinase I/glycogen synthase kinase-3β..Acta Crystallographica Section D56.2000,561464-1465. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105132393A (zh) * 2015-09-12 2015-12-09 复旦大学 一种深海耐盐、耐碱蛋白酯酶的表达和纯化、晶体结构及其应用

Also Published As

Publication number Publication date
WO2003068932A2 (fr) 2003-08-21
EP1504368A2 (fr) 2005-02-09
WO2003068932A8 (fr) 2005-06-02
AU2003225569A8 (en) 2003-09-04
WO2003068932A3 (fr) 2004-12-16
CN1630863A (zh) 2005-06-22
EP1504368A4 (fr) 2008-01-23
JP2005532265A (ja) 2005-10-27
AU2003225569A1 (en) 2003-09-04
US20070264699A1 (en) 2007-11-15
US20070020745A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
EP1549318B1 (fr) Structure cristalline de la proteine aurora-2 et poches de liaison associees
Xiao et al. Phosphorylation releases constraints to domain motion in ERK2
De La Sierra et al. X-ray structure of TMP kinase from Mycobacterium tuberculosis complexed with TMP at 1.95 Å resolution
US20050196851A1 (en) Crystal structure of the BTK kinase domain
US6387641B1 (en) Crystallized P38 complexes
JP2006221669A (ja) ＧＳＫ−３βタンパク質の特徴づけおよびその使用方法
Ramatenki et al. Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer
CN1630863B (zh) 人gsk3的结晶方法及其新的晶体结构
EP1578687A2 (fr) Structure cristalline de la mapkap kinase-2 humaine
US20070020253A1 (en) Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof
Leonidas et al. Binding of Phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X‐ray crystallography
US20090186394A1 (en) Crystallizable JNK complexes
US20050261836A1 (en) Crystal structure of mitogen-activated protein kinase-activated protein kinase 2 and binding pockets thereof
Ranatunga et al. Structural studies of the Nudix hydrolase DR1025 from Deinococcus radiodurans and its ligand complexes
Setti et al. Potency and pharmacokinetics of broad spectrum and isoform-specific p110 γ and δ inhibitors in cancers
US7584087B2 (en) Structure of protein kinase C theta
US20040009569A1 (en) Kinase crystal structures and materials and methods for kinase activation
WO2003104481A2 (fr) Procedes
US20030077803A1 (en) Crystals of the escherichia coli membrane-associated glycosyltransferase (MurG) protein, atomic coordinates and three dimensional structures thereof, atomic coordinates and three dimensional structures of binding domains thereof, images thereof, and methods of crystallizing MurG proteins models of UDP glycosyltransferases, MurG proteins and binding sites methods of making models, methods of using models of MurG, compounds that bind, inhibit or stimulate MurG proteins, and therapeutic compositions thereof
WO2003074001A2 (fr) Procede de conception d'inhibiteurs specifiques pour la proline isomerase de la proteine pin1 et molecules associees a la proteine pin1
US7135319B2 (en) Crystals of an acyl carrier protein synthase/acyl carrier protein complex
US20030032649A1 (en) Chimerizing protein kinases for drug discovery
US20040005687A1 (en) Kinase crystal structures
US7303892B1 (en) Crystallization of AKT3
WO2009019484A1 (fr) Structure cristalline d'ampk et ses utilisations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100609

Termination date: 20110211